Targeting autophagic pathways for cancer drug discovery
Bo Liu, Jin-Ku Bao, Jin-Ming Yang, Yan Cheng
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, School of Life Sciences, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
[Abstract] Autophagy, an evolutionarily conserved lysosomal degradation process, has drawn an increasing amount of attention in recent years for its role in a variety of human diseases, such as cancer. Notably, autophagy plays an important role in regulating several survival and death signaling pathways that determine cell fate in cancer. To date, substantial evidence has demonstrated that some key autophagic mediators, such as autophagy-related genes (ATGs), PI3K, mTOR, p53, and Beclin-1, may play crucial roles in modulating autophagic activity in cancer initiation and progression. Because autophagy-modulating agents such as rapamycin and chloroquine have already been used clinically to treat cancer, it is conceivable that targeting autophagic pathways may provide a new opportunity for discovery and development of more novel cancer therapeutics. With a deeper understanding of the regulatory mechanisms governing autophagy, we will have a better opportunity to facilitate the exploitation of autophagy as a target for therapeutic intervention in cancer. This review discusses the current status of targeting autophagic pathways as a potential cancer therapy.
Chinese Journal of Cancer
Volume 32·Issue 3·2013 Page: 113-120 [ PDF Full-text